Metformin and Aging: A Review

Area of Science:

• Gerontology
• Pharmacology
• Metabolic Diseases

Background:

• Metformin, a common type 2 diabetes drug, is being explored for anti-aging properties based on preclinical data and retrospective studies.
• Emerging research suggests potential health benefits extending beyond glycemic control.

Purpose of the Study:

• To evaluate metformin's efficacy as an anti-aging intervention in a broader population.
• To investigate the impact of metformin on aging-related endpoints like frailty.
• To assess potential risks and side effects associated with long-term metformin use in non-diabetic individuals.

Main Methods:

• Ongoing large-scale, prospective, placebo-controlled clinical trials.
• Analysis of preclinical data from lower-order organisms.
• Review of retrospective health outcome data in type 2 diabetics.
• Consideration of senolytic drugs as a comparable anti-aging approach.

Main Results:

• Preclinical evidence and retrospective data suggest metformin may have anti-aging effects.
• Clinical trials are underway to confirm these findings in aging populations.
• Potential concerns include vitamin B12 and B6 deficiencies.
• Adverse effects on cardiovascular fitness from exercise in conjunction with metformin require further investigation.

Conclusions:

• Metformin is a candidate for repositioning as an anti-aging therapy.
• Further research is crucial to establish its safety and efficacy profile in non-diabetic aging individuals.
• Potential side effects necessitate careful monitoring and consideration of individual health profiles.